A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Public ClinicalTrials.gov record NCT06005974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.
Study identification
- NCT ID
- NCT06005974
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 18 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 14, 2024
- Primary completion
- Feb 23, 2025
- Completion
- Feb 23, 2025
- Last update posted
- Feb 22, 2026
2024 – 2025
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Eastern Connecticut Hematology & Oncology Associates | Norwich | Connecticut | 06360 | — |
| Medical Oncology Hematology Consultants | Newark | Delaware | 19713 | — |
| Cancer Specialists of North Florida | Fleming Island | Florida | 32003 | — |
| Mission Cancer And Blood | Des Moines | Iowa | 50314 | — |
| American Oncology Partners of Maryland, PA | Bethesda | Maryland | 20817 | — |
| Saint Luke's Hospital | Kansas City | Missouri | 64111 | — |
| Hunterdon Hematology Oncology | Hillsborough | New Jersey | 08844 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Mary Crowley Cancer Research Centers | Dallas | Texas | 75231 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06005974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06005974 live on ClinicalTrials.gov.